chromosomal microarray

Lineagen hopes to use PWNHealth's consumer-oriented model to expand access to its testing services for developmental delay and autism spectrum disorder.

Although the two studies seem to provide conflicting results on the impact of PGS, the "devil's in the details," according to an outside expert.

Invitae is interested in companies that can contribute positively to its revenues in the next two to three quarters, according to CEO Sean George. 

The acquisitions will enable Invitae to add reproductive health genetic testing to its portfolio and become what it calls a "comprehensive genomic information company." 

The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.

CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.

The company's testing was successful in more than 90 percent of cases over almost four years, and detected a wide variety of abnormalities.

Ambry's new lab provides a streamlined, automated workflow that has allowed the company to triple its daily testing volume since it opened more than four months ago. 

The company reported an 18 percent increase in the number of reproductive health tests completed during the quarter. 

Low-coverage, whole-genome sequencing had a diagnostic yield of up to 53 percent in prenatal and postnatal samples referred for chromosomal analyses.

Pages

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.